<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: MGb2, a mouse-derived monoclonal antibody specific to gastric <z:mp ids='MP_0002038'>carcinoma</z:mp>, was developed in our laboratory </plain></SENT>
<SENT sid="1" pm="."><plain>Nevertheless, the potential role of MGb2-antigen/TRAK1 (MGb2-Ag/TRAK1) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to investigate the relationship between MGb2-Ag/TRAK1 expression and the clinicopathological characteristics of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The potential utility of MGb2-Ag/TRAK1 expression as a prognostic indicator was also evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Immunohistochemistry and western blot were used to detect MGb2-Ag/TRAK1 expression in 140 CRC tissues </plain></SENT>
<SENT sid="5" pm="."><plain>The relationship between MGb2-Ag/TRAK1 expression and clinicopathological characteristics and postoperative survival time was statistically analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: MGb2-Ag/TRAK1 expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues was significantly higher than in <z:mpath ids='MPATH_458'>normal</z:mpath> tissues and was positively correlated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation (p = 0.006), invasion (p = 0.049), and pathological stage (p = 0.032) </plain></SENT>
<SENT sid="7" pm="."><plain>There was no significant difference between MGb2-Ag/TRAK1 expression and the age or gender of the patient, lymphatic invasion, or distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (p = 0.586, 0.308, 0.910, and 0.068, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>The survival time of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with high expression of MGb2-Ag/TRAK1 was shorter than the survival time of patients with low MGb2-Ag/TRAK1 expression </plain></SENT>
<SENT sid="9" pm="."><plain>Both univariate and multivariate analyses showed that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation and MGb2-Ag/TRAK1 expression were two independent and prognostic factors for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (p &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: MGb2-Ag/TRAK1 may play an important role in the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and may be a valuable prognostic indicator of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>